Introduction {#s1}
============

In the 21st century, malaria is still regarded as a major global infectious disease, with a high pediatric mortality toll in the Developing World. Chemotherapy is a central tool for management of the disease. Unfortunately, the *Plasmodium falciparum* parasite, the most deadly human malaria pathogen, has shown an extraordinary ability to develop resistance to all antimalarials employed. From the first reports involving quinine [@pone.0020212-RodriguesCoura1], to the ultimate demise of chloroquine in the late 20^th^ century, drug resistance has been a central factor in the expansion of the disease, associated with massive mortality and morbidity [@pone.0020212-Trape1]. Now, in the 21st century, the introduction of new treatment strategies centered on the combinatorial use of short lived artemisinin derivatives with long half-life drugs (artemisinin combination therapy, ACT) has been able to halt resistance and disease spread for the first time in decades. After its spectacular decrease in incidence following ACT introduction in some regions [@pone.0020212-Bhattarai1], this has encouraged optimism for the prospects of eliminating malaria entirely [@pone.0020212-WHOwebsite1]. Unfortunately, *P. falciparum* is again demonstrating its remarkable capacity to evolve mechanisms of avoiding drug action. Among the presently employed ACT drugs, decreased sensitivity has been reported to all the quinoline partner drugs in use, including amodiaquine [@pone.0020212-Holmgren1]--[@pone.0020212-Picot1], lumefantrine [@pone.0020212-Price1], [@pone.0020212-Sisowath1] and mefloquine [@pone.0020212-Price2]. More recently, *P.falciparum* isolates in Cambodia were shown to have developed tolerance to artemisinin, the core component of the combinations [@pone.0020212-Noedl1], [@pone.0020212-Dondorp1]. This tolerance is characterized by prolonged parasite clearance after treatment [@pone.0020212-Dondorp1].

For most ACT partner drugs, the mechanisms behind antimalarial drug resistant phenotypes are known to be dependent on alterations in the food vacuole localized proteins Pgh-1 (*pfmdr1*) and PfCRT (*pfcrt*). Both PfCRT and Pgh-1 are drug transporters believed to contribute to *P. falciparum* drug resistance through the decrease of antimalarial accumulation in the target cellular compartment. PfCRT transports drugs from the food vacuole lumen to the cytoplasm [@pone.0020212-Bray1], [@pone.0020212-Sanchez1], an action particularly important to the development of resistance, considering that several antimalarials, such the 4-aminoquinolines amodiaquine, desethylamodiaquine and chloroquine, act in this organelle. In contrast, Pgh-1 has been proposed to actively pump drugs from the cytoplasm towards the food vacuole [@pone.0020212-Rohrbach1], which is protective against antimalarials operating on cytoplasmic targets. Such agents putatively include the aminoalcohol-quinolines (AAQs) [@pone.0020212-Price2], and possibly artemisinin and its derivatives [@pone.0020212-Price3].

There is an emerging idea that these resistance phenomena actually involve genetic contributions beyond the genes already mentioned [@pone.0020212-Dahlstrom1], [@pone.0020212-Mu1]. Accordingly, it is likely that another player could be added to the two transmembrane proteins discussed earlier: the parasite multidrug resistance protein homologue, PfMRP1 [@pone.0020212-Klokouzas1]--[@pone.0020212-Kavishe1]. This class of ABC transporter is involved in drug evasion in a large range of organisms, and likely plays a similar function in *P. falciparum*. In support of this, *pfmrp1* has been proposed to participate in *in vivo* and/or *in vitro* parasite response to chloroquine [@pone.0020212-Mu1], [@pone.0020212-Raj1], quinine [@pone.0020212-Mu1], [@pone.0020212-Parquet1], lumefantrine [@pone.0020212-Dahlstrom1] and artemisinin [@pone.0020212-Raj1].

A full account of the simultaneous participation of each of these genes in parasite drug susceptibility to multiple drugs has not yet been performed in detail, in part due to the diversity of their full open reading frame (ORF). In this report, we have characterized the phenotype and genotype of a set of *P. falciparum* adapted parasites from the area of Mae Sot, Western Thailand-a known epicenter for multidrug resistance. The work has unveiled different genetic backgrounds containing a combination of different polymorphisms associated with resistance to antimalarial drugs used in ACT.

Results {#s2}
=======

*In vitro* antimalarial drug susceptibility {#s2a}
-------------------------------------------

50% and 90% inhibitory concentration (IC~50~ and IC~90~) values were measured for artemisinin (ART), dihydroartemisinin (DHA), mefloquine (MQ) and lumefantrine (LUM) in 46 parasite field isolates originating from the Thai-Myanmar border. A relatively large range in IC values was observed for most of the antimalarials tested, including the artemisinin-type drugs. For these, the median IC~50~ values (Max-Min) were 7.4 nM (1.2--19.5 nM) for ART and 1.2 nM (0.3--5.3 nM) for DHA. For the arylaminoalcohols, IC~50~ values were: MQ and LUM, 92.5 nM (16.5--270.8 nM) and 11.9 nM (2.0--40.8 nM), respectively ([Figure 1](#pone-0020212-g001){ref-type="fig"} and isolates individual data in [Table S1](#pone.0020212.s002){ref-type="supplementary-material"}).

![*In vitro* antimalarials 50% inhibition concentration variance within the isolates.\
Data are represented in boxplot. The lower and upper quartiles of the box are 25^th^ and 75^th^ percentile, respectively and the band near the middle of the box is the median. End of the whiskers represent the 10^th^ and 90^th^ percentile. Dots represent outliers.](pone.0020212.g001){#pone-0020212-g001}

There is a significant correlation between the parasitic response to structurally associated drugs such as sesquiterpene lactone (ART and DHA) and aminoalcohol quinolines (MQ and LUM) ([Table 1](#pone-0020212-t001){ref-type="table"}). Interestingly, even though not structurally similar, the amino alcohol quinolines group and the artemisinin-type compounds form a cluster of cross response (P\<0.001).

10.1371/journal.pone.0020212.t001

###### Correlations of *in vitro* IC\'s values between the different drugs tested in 46 field isolates as well as associations between the IC\'s values and the major polymorphisms in *pfmdr1* and *pfmrp1* genes.

![](pone.0020212.t001){#pone-0020212-t001-1}

                    *In vitro* drug IC\'s significance[§](#nt101){ref-type="table-fn"}   *pfmdr1* polymorphisms significance[¤](#nt102){ref-type="table-fn"}   *pfmrp1* polymorphisms significance[¤](#nt102){ref-type="table-fn"}                                                                                                                                                                                        
  ---------------- -------------------------------------------------------------------- --------------------------------------------------------------------- --------------------------------------------------------------------- -------------------- -------------------- -------------------- -------------------- ------- ------- ------- ------- ----------- ------------- ------- ------- ------- ------- ------- -----------
  **ART IC~50~**                            **\<0.001** (0.97)                                                   **\<0.001** (0.68)                                                    **\<0.001** (0.66)                            **\<0.001** (0.82)   **\<0.001** (0.69)   **\<0.001** (0.88)   **\<0.001** (0.80)   0.855   0.155   0.855   0.528   **0.003**   **\<0.001**   0.628   0.141   0.181   0.791   0.181   **0.007**
  **ART IC~90~**                                                                                                  **\<0.001** (0.6)                                                    **\<0.001** (0.63)                            **\<0.001** (0.82)   **\<0.001** (0.73)   **\<0.001** (0.81)   **\<0.001** (0.77)   0.942   0.353   0.942   0.626   **0.005**   **\<0.001**   0.533   0.120   0.145   0.623   0.145   **0.004**
  **DHA IC~50~**                                                                                                                                                                       **\<0.001** (0.90)                             **0.001** (0.49)     **0.027** (0.33)    **\<0.001** (0.70)   **\<0.001** (0.54)   0.395   0.467   0.395   0.596     0.354        0.284      0.925   0.744   0.416   0.926   0.416     0.163
  **DHA IC~90~**                                                                                                                                                                                                                      **0.004** (0.41)     **0.075** (0.27)    **\<0.001** (0.63)   **\<0.001** (0.51)   0.974   0.538   0.974   0.870     0.292        0.152      0.925   0.566   0.398   0.922   0.398     0.192
  **MQ IC~50~**                                                                                                                                                                                                                                           **\<0.001** (0.96)   **\<0.001** (0.81)   **\<0.001** (0.80)   0.606   0.249   0.606   0.342   **0.004**   **\<0.001**   0.835   0.116   0.174   0.722   0.174   **0.003**
  **MQ IC~90~**                                                                                                                                                                                                                                                                **\<0.001** (0.66)   **\<0.001** (0.72)   0.458   0.389   0.458   0.233   **0.004**   **\<0.001**   0.886   0.063   0.113   0.976   0.113   **0.004**
  **LUM IC~50~**                                                                                                                                                                                                                                                                                    **\<0.001** (0.90)   0.527   0.163   0.527   0.320   **0.004**   **\<0.001**   0.755   0.238   0.209   0.801   0.209   **0.015**
  **LUM IC~90~**                                                                                                                                                                                                                                                                                                         0.181   0.249   0.181   0.087   **0.001**   **\<0.001**   0.526   0.124   0.224   0.903   0.224   **0.022**

Cells show P-value (2-tailed) and in brackets the Pearson correlation coefficient between the IC\'s values of the different antimalarial tested in the isolates. P value\<0.05 is considered significant (2-tailed).

Cells show P-value (2-tailed) of the linear association analysis between the main polymorphisms found in the isolates ([Table 2](#pone-0020212-t002){ref-type="table"}) and the *in vitro* drug IC\'s values. Isolates that harbors both alleles (mixed infection) in the determined polymorphic region were excluded from the statistical analysis. T-test with equal variances assumed was used to test differences. Bold numbers are considered significant for T-test (P\<0.05). For comparison, Bonferroni-adjusted levels of significance would be: P value\<0.0042.

ART: artemisinin, DHA: dihydroartemisinin, MQ: mefloquine, LUM: lumefantrine, IC~50~ and IC~90~: Inhibition Concentration of 50% and 90%. CNV: copy number variation.

Polymorphisms detected in *pfmdr1*, *pfmrp1* and *pfcrt* {#s2b}
--------------------------------------------------------

Sequence analysis of the full *pfmdr1* open reading frame (ORF) within the isolates revealed 7 SNPs, including two well studied polymorphic amino acid positions (Y184F and N1042D), as well as 4 other non-synonymous at positions E130K, A750T, S784L, F1226Y, recently described in parasites from Western Cambodia [@pone.0020212-Imwong1], and one synonymous at genomic position a747g ([Table 2](#pone-0020212-t002){ref-type="table"}). Three variants were found within the triplet nucleotide AAT microsatellite hinge located near the central region of the gene ([Table 2](#pone-0020212-t002){ref-type="table"}) where 31/46 of the isolates carry an insertion of one more AAT relative to 3D7 clone reference. Sequencing chromatograms of this gene revealed one isolate with mixed infection present at amino acid position 130, 249 and 750.

10.1371/journal.pone.0020212.t002

###### Single Nucleotide Polymorphisms in the studied transporter genes.

![](pone.0020212.t002){#pone-0020212-t002-2}

              Nucleotide position   Triplet nucleotide change   Amino acid position   Amino acid change   Frequency (proportion)
  ---------- --------------------- --------------------------- --------------------- ------------------- ------------------------
  *pfmdr1*                                                                                               
                      388                    GAA-AAA                    130                  E-K             0.13 (6/46)+1mix
                      551                    TAT-TTT                    184                  Y-F               0.09 (4/46)
                      747                    GGA-GGG                    249                  syn             0.13 (6/46)+1mix
                  1972--1980                del 3xAAT                   658               \_ \_ \_             0.09 (4/46)
                  1978--1980                 del AAT                    660                  \_                0.24 (11/46)
                     1980                    ins AAT                   660+1                 +N                0.67 (31/46)
                     2248                    GCA-ACA                    750                  A-T             0.15 (7/46)+1mix
                     2351                    TCA-TTA                    784                  S-L               0.02 (1/46)
                     3124                    AAT-GAT                   1042                  N-D               0.02 (1/46)
                     3677                    TTT-TAT                   1226                  F-Y            0.50 (23/46)+1mix
  *pfmrp1*                                                                                               
                      300                    GCA-GCT                    100                  syn               0.04 (2/46)
                      571                    CAT-TAT                    191                  H-Y               0.96 (44/46)
                      974                    AAT-AGT                    325                  N-S             0.20 (9/46)+1mix
                     1309                    TCA-GCA                    437                  S-A               0.96 (44/46)
                     1716                    TTC-TTG                    572                  F-L            0.39 (18/46)+1mix
                     2353                    CAT-AAT                    785                  H-N            0.50 (23/46)+1mix
                     2626                    ATA-GTA                    876                  I-V            0.74 (34/46)+1mix
                     3020                    ACG-ATG                   1007                  T-M            0.50 (23/46)+1mix
                     3603                    GAA-GAG                   1201                  syn               0.04 (2/46)
                     4168                    TTT-ATT                   1390                  F-I             0.17 (8/46)+2mix
                     4451                    GAA-GGA                   1484                  E-G               0.02 (1/46)
  *pfcrt*                                                                                                
                      222                    ATG-ATT                    74                   M-I                1 (46/46)
                      223                    AAT-GAT                    75                   N-D                1 (46/46)
                      225                    AAT-GAA                    75                   N-E                1 (46/46)
                      227                    AAA-ACA                    76                   K-T                1 (46/46)
                      658                    GCC-TCC                    220                  A-S                1 (46/46)
                      811                    CAA-GAA                    271                  Q-E                1 (46/46)
                      977                    AAC-AGC                    326                  N-S                1 (46/46)
                     1067                    ATA-ACA                    356                  I-T                1 (46/46)
                     1112                    AGA-ATA                    371                  R-I                1 (46/46)

All Thai isolates carry an asparagine residue at position 86 and the SNP with the highest frequency detected was the F1226Y with 23/46 (50%) isolates being 1226Y. The remaining SNPs were found with low frequency ([Table 2](#pone-0020212-t002){ref-type="table"}). Twenty six of the 46 isolates analyzed carried increased *pfmdr1* copy number, as detected by realtime PCR. Specifically, 18 carried two copies, while 8 carried more than three copies ([Table S1](#pone.0020212.s002){ref-type="supplementary-material"}).

Analysis of the sequencing chromatograms of the *pfmrp1* gene revealed one isolate with mixed infection present at a.a. position 325, 572, 785, 876 and 1007. This isolate does not correspond to the same mixed isolate detected with *pfmdr1* gene sequencing. In total 11 SNPs (of which 2 synonymous) were identified in the *pfmrp1* ORF. All of these SNPs were published following our previous global survey of the biodiversity of this gene [@pone.0020212-Dahlstrom1]. SNPs at positions 191, 325, 437, 572, 785, 876, 1007, 1390 were found in the isolates with elevated occurrence ([Table 2](#pone-0020212-t002){ref-type="table"}). Increased *pfmrp1* gene copy number was not detected.

The *pfcrt* full open reading frame of each isolate sequenced from cDNA revealed that all isolates (46/46) carried the *pfcrt* Dd2-like open reading frame (ORF) haplotype (C72 /74I/75E/76T/220S/271E/326S/356T/371I) ([Table 2](#pone-0020212-t002){ref-type="table"}).

After the *in vitro* analysis in the laboratory for drug susceptibility, the DNA was extracted from all isolates again to check for variance and/or selection. The recheck was solely performed in the polymorphisms with significant association with the *in vitro* phenotype. These were the *pfmdr1* CNV, as well as the *pfmdr1* F1226Y and *pfmrp1* F1390I SNPs. Comparison of the DNA extracted before and after the parasites *in vitro* adaptation and expansion, revealed that two isolates lost copies in *pfmdr1* gene during the procedure, changing from 2 to 1 copy ([Table S1](#pone.0020212.s002){ref-type="supplementary-material"}). Out of the 46 isolates analyzed, 24 carried increased *pfmdr1* copy number, specifically, 16 carried two copies, while 8 carried more than three copies. Pyrosequencing of position F1226Y in *pfmdr1* and F1390I in *pfmrp1* performed in the DNA extracted after the drug susceptibility tests, revealed isolates with mixed infections (both alleles) at these polymorphic regions. [Table S1](#pone.0020212.s002){ref-type="supplementary-material"} specifies the characteristics of each isolate including the individual genotype before and after the drug susceptibility tests performed.

[Table 2](#pone-0020212-t002){ref-type="table"} shows the genotype frequency of these three most relevant polymorphisms, from the re-extracted DNA, as this would reflect the genotype at that point in time. [Table 1](#pone-0020212-t001){ref-type="table"} also shows statistical values using data from the re-extracted DNA analysis for these three polymorphisms as this will reflect a more valid association with the *in vitro* drug susceptibility tests performed. To note that this genotype variance before and after adaptation, did not change the determined statistically significant genotype-phenotype association.

*In vitro* phenotype-genotype associations {#s2c}
------------------------------------------

Since all isolates had the same haplotype for the *pfcrt* gene, a possible association could not be assessed between the *pfcrt* SNPs and IC\'s values. As previously observed [@pone.0020212-Price1], [@pone.0020212-Price2], [@pone.0020212-Price3], [@pone.0020212-Cowman1], and herein confirmed, an increased gene copy number of *pfmdr1* was clearly associated with higher IC~50~\'s for MQ, LUM and ART (P\<0.0042) ([Table 1](#pone-0020212-t001){ref-type="table"}, [Figure 2](#pone-0020212-g002){ref-type="fig"}). From the seven SNPs found in *pfmdr1,* only one, F1226Y, was found to be associated with decreased sensitivity to ART, MQ and LUM IC~50~ and IC~90~ ([Table 1](#pone-0020212-t001){ref-type="table"}, [Figure 3](#pone-0020212-g003){ref-type="fig"}). The average IC~50~ (±SE) of the *pfmdr1* 1226Y allele was 10.09(±1.12), 135.18(±14.57), and 17.77(±1.95) nM, values significantly higher compared with the non-carriers: 5.43(±0.98), 73.06(±14.08) and 9.47(±1.90) nM, for each drug, respectively. Among the 11 SNPs found in *pfmrp1* ([Table 2](#pone-0020212-t002){ref-type="table"}), F1390I was documented to significantly modulate the *in vitro* drug response phenotypes ([Table 1](#pone-0020212-t001){ref-type="table"}). Carriers of the F1390 allele were less susceptible to ART, MQ and LUM, with average IC~50~\'s of 8.96(±0.92), 121.71(±12.17) and 15.56(±1.71) nM, compared to 1390I carriers with values of 3.30(±0.86), 37.25 (±9.31) and 6.08(±1.87) nM, respectively ([Figure 4](#pone-0020212-g004){ref-type="fig"}). Interestingly, even though *pfmdr1* F1226Y and *pfmrp1* F1390I alleles have very similar association profiles, both seem to represent independent actions, as they were not found together in the same Thai isolate in more instances than would randomly be expected (P\>0.05).

![Significant association of *pfmdr1* copy number variation and in vitro IC~50~\'s for ART, MQ and LUM.\
Significant relationship between average *in vitro* drugs tested IC~50~\'s and *pfmdr1* CNV polymorphism. Data described in [Table S2](#pone.0020212.s003){ref-type="supplementary-material"}. \<1.5: 1 gene copy of *pfmdr1* (\#22 isolates). \>1.5: 2 and 3 gene copies of *pfmdr1* (\#24 isolates). T-test statistics was applied. P value \<0.0042 is consider significant after Bonferroni correction. Error bars represent SE.](pone.0020212.g002){#pone-0020212-g002}

![Significant association of *pfmdr1* F1226Y and IC~50~\'s for ART, MQ and LUM.\
Significant relationship between average *in vitro* drugs tested IC~50~\'s and *pfmdr1* F1226Y polymorphism. Data described in [Table S2](#pone.0020212.s003){ref-type="supplementary-material"}. Black bars are average IC~50~ of 22 isolates with F1226 allele. Grey bars are average IC~50~ of 23 isolates with 1226Y allele. T-test statistics was applied. P value \<0.0042 is consider significant after Bonferroni correction. Error bars represent SE.](pone.0020212.g003){#pone-0020212-g003}

![Significant association of *pfmrp1* F1390I and IC~50~\'s for ART, MQ and LUM.\
Significant relationship between average *in vitro* drugs tested IC~50~\'s and *pfmrp1* F1390I polymorphism. Data described in [Table S2](#pone.0020212.s003){ref-type="supplementary-material"}. Black bars are average IC~50~ of 36 isolates with F1390 allele. Grey bars are average IC~50~ of 8 isolates with 1390I allele. T-test statistics was applied. P value \<0.0042 is consider significant after Bonferroni correction. Error bars represent SE.](pone.0020212.g004){#pone-0020212-g004}

We have further analyzed the effects of the available combinations (haplotypes) of the most relevant polymorphisms, i.e. the *pfmrp1* F1390I and *pfmdr1* F1226Y SNPs, as well as *pfmdr1* gene copy number variation (CNV). In particular, a trend for an identical progressive increase in IC~50~ was evident for the antimalarials ART, MQ and LUM ([Figure 5](#pone-0020212-g005){ref-type="fig"}), associated with the following sequence of haplotypes (from more sensitive to more **resistant** associated):

i.  IF1: *pfmrp1* 1390I+*pfmdr1* F1226+*pfmdr1* CNV\<1.5;

ii. **F**F1: *pfmrp1* F1390+*pfmdr1* F1226+*pfmdr1* CNV\<1.5;

iii. **FY**1: *pfmrp1* F1390+*pfmdr1* 1226Y+*pfmdr1* CNV\<1.5;

iv. **F**F**2:** *pfmrp1* F1390+*pfmdr1* F1226+*pfmdr1* CNV\>1.5;

v.  **FY2:** *pfmrp1* F1390+*pfmdr1* 1226Y+*pfmdr1* CNV\>1.5.

![Haplotype and *in vitro* IC~50~\'s association.\
Relationship between average *in vitro* drug tested IC~50~\'s and *pfmrp1* F1390I, *pfmdr1* F1226Y and *pfmdr1* CNV polymorphisms. Bars represent different haplotypes. IF1 (\#6 isolates): *pfmrp1* 1390I, *pfmdr1* F1226 and 1 gene copy of *pfmdr1*. FF1 (\#9 isolates): *pfmrp1* F1390, *pfmdr1* F1226 and 1 gene copy of *pfmdr1*. FY1 (\#5 isolates): *pfmrp1* F1390, *pfmdr1* 1226Y and 1 gene copy of *pfmdr1*. FF2 (\#6 isolates): *pfmrp1* F1390, *pfmdr1* F1226 and \>1 gene copy of *pfmdr1*. FY2 (\#15 isolates): *pfmrp1* F1390, *pfmdr1* 1226Y and \>1 gene copy of *pfmdr1*. T-test statistics was applied to see significant difference between haplotypes. \*: P\<0.05. Error bars represent SE.](pone.0020212.g005){#pone-0020212-g005}

Crystal structures of ABC transporters from *P. falciparum* are still not available. In lieu of this, an approach based on computational molecular modeling with known reference structures was applied to explore putative functional implications of relevant polymorphisms.

As we previously reported [@pone.0020212-Dahlstrom1], PfMRP1 contains 12 transmembranes domains (TMs) and 2 NBDs, presenting a full ABC transporter structure (i.e. 6+6 TMs), similar to Pgh-1 [@pone.0020212-Peel1]. Residue 1390 is expected to be localized in transmembrane 11 ([Figure 6A](#pone-0020212-g006){ref-type="fig"}). Based on the Msba ABC transporter crystal 3B60 and using HHpred, a homology detection and structure prediction server, we were able to develop a model for the second transmembrane spanning domain 2 ([Figure 6B](#pone-0020212-g006){ref-type="fig"}).

![2D structure of PfMRP1 and F1390I SNP location.\
A: Secondary structure analysis of transmembrane spanning domain 2 (TSD2) of PfMRP1 and F1390I SNP localization. B: Computational homology modelling was performed at HHpred. Alignment for best template was performed using Psi-blast and with local alignment. The template from the best E-score alignment was based in the Msba ABC transporter crystal 3B60 then used in Modeller software to generate a model. Models were visualized with Yasara software.](pone.0020212.g006){#pone-0020212-g006}

The residues 1034 and 1042 of Pgh-1 are located in TM11, an important domain for antimalarial resistance [@pone.0020212-Sidhu1]. This is likely due to alterations in a drug pocket region of the transporter. Similarly, the involvement of polymorphisms related to antimalarial resistance in TM11 of PfMRP1 suggests the existence of a drug-binding pocket in this region. Amino acid residue 1226 in Pgh-1 is localized in a non-conserved insertion in the reference structure, not allowing the possibility to perform homology modeling.

Discussion {#s3}
==========

The global implementation of ACT has led to a significant world-wide reduction in malaria incidence. This, in turn, has motivated policymakers and donors to adopt a more optimistic view of the prospect of eliminating malaria completely in vast tropical endemic regions [@pone.0020212-WHOwebsite1]. In order to make this a reality, and considering the epidemiological consequences of chloroquine resistance [@pone.0020212-Trape1], we must understand the mechanisms behind incidences of parasite resistance to ACT. This is particularly urgent, as there is accumulating evidence of development of resistance in the field - or at least significant decreases in parasite response against artemisinin derivatives [@pone.0020212-Noedl1], [@pone.0020212-Dondorp1] and to the long half-life ACT partner drugs [@pone.0020212-Holmgren2], [@pone.0020212-Sisowath1], [@pone.0020212-Price2], [@pone.0020212-Price3], [@pone.0020212-Sisowath2], [@pone.0020212-Sisowath3].

Through the search for drug resistance molecular markers, as expressed by their modulation of the specific parasite antimalarial *in vitro* IC\'s, our results reinforced the importance of *pfmdr1* copy number as a central factor in the response of *P. falciparum* to drugs of different structures. The association between increased copy number and decreased sensitivity to ART, MQ and LUM confirms previous associative data *in vivo* [@pone.0020212-Price1], [@pone.0020212-Price2], as do strictly controlled gene knock-down experiments in parasite clones [@pone.0020212-Sidhu2].

Most relevant, we have identified SNPs that constitute new drug resistance candidate markers. These are comprised of two recently described polymorphisms: *pfmdr1* F1226Y [@pone.0020212-Imwong1] and *pfmrp1* F1390I [@pone.0020212-Dahlstrom1]. Structural analysis performed for polymorphism F1390I in PfMRP1 showed it to be localized within transmembrane 11, which has been proposed to be part of a substrate pocket in several ABC transporters, including Pgh-1. The similar localization and involvement of this polymorphism for antimalarial resistance suggests it has an analogous roll to the S1034C and N1042D SNPs observed in Pgh-1 [@pone.0020212-Sidhu1], [@pone.0020212-Reed1]. Importantly, directed mutagenesis studies performed in the human and murine PfMRP1 have pointed to TM16, putatively equivalent to the PfMRP1 TM11 in functional terms, as a central component that defines transport specificity [@pone.0020212-Koike1]--[@pone.0020212-Daoud1]. In this context, it is conceivable that the TM11 located F1390I SNP is changing the specificity of the interactions between the PfMRP1 and the antimalarials ART, MQ and LUM .

The *pfmdr1* F1226Y and *pfmrp1* F1390I SNPs seem to have an inter-independent, but very similar quantitative effect on the simultaneous response *in vitro* drug susceptibility of the parasite against the ART/MQ/LUM, which to a certain extent parallels what is observed with the *pfmdr1* increased copy number. In particular, successive accumulation of these SNPs, combined with the presence of *pfmdr1* CNV polymorphism, seem to have a cumulative contribution ([Figure 5](#pone-0020212-g005){ref-type="fig"}). As for the *pfmdr1* F1226Y SNP, it is conceivable that, as previously proposed for the *pfmdr1* 86N allele [@pone.0020212-Hastings1], its presence might enhance the contribution of the increased copy number of this gene. The preferential presence of F1226Y among the analyzed isolates with *pfmdr1* copy number amplifications might hence be the result of a drug driven selection, reinforcing the notion that the phenotypical consequences of the *pfmdr1* CNV polymorphism is modulated by the nature of the ORF sequence involved.

In this work we unveil a potential new candidate pathway towards resistance, particularly important for two of the most important ACTs used worldwide: artemether-LUM (Coartem^®^, Novartis, Basel) and artesunate-MQ (Artequin Paediatric^®^, Mepha Ltd, Aesch, Switzerland). It would be of interest to retrospectively explore *in vivo* trials with these combinations in search of confirmatory selection events for these mutations, in particular the case of artesunate-MQ, the definition of two categories of *pfmdr1* CNV. For the F1226Y SNP, its association with clinical failure might be of relevance. Interpreting the *pfmrp1* F1390I/ *pfmdr1* F1226Y/ *pfmdr1* CNV haplotype analysis, two observations deserve mention as is evident from [figure 5](#pone-0020212-g005){ref-type="fig"}. The introduction of the *pfmdr1* CNV is associated with an abrupt leap in MQ IC~50~ values, confirming the well established status of this type of mutation as a valuable specific marker for *P. falciparum* resistance against MQ [@pone.0020212-Price2], [@pone.0020212-Price3], [@pone.0020212-Cowman2]. The *pfmdr1* CNV alone seems to have a less dramatic but significant effect against ART and LUM, again confirming previous findings [@pone.0020212-Price1], [@pone.0020212-Price2], [@pone.0020212-Sidhu1]. Fortunately, ART is not commonly used in ACT; the partners of LUM and MQ being artemether and artesunate, respectively.

Although previous reports have shown association of *pfmdr1* CNV with artesunate and DHA [@pone.0020212-Price1], [@pone.0020212-Price2], this study did not find any significant association of DHA with *pfmdr1* CNV neither with *pfmrp1* F1390I or *pfmdr1* F1226Y. Nevertheless, it showed significant positive correlation with ART, MQ and LUM *in vitro* susceptibility responses ([Table 1](#pone-0020212-t001){ref-type="table"}).

Taken together, these data point towards the necessity for further research defining molecular markers for the development of resistance against the artemisinin derivative+amino-alcohol quinoline partner drugs, as these two structurally different classes of antimalarials seem to share, at least to some extent, mechanisms of drug action evasion. The *pfmrp1* F1390I and *pfmdr1* F1226Y SNPs, in conjugation with the well established *pfmdr1* CNV, represent likely candidates. The selection of these SNPs might be a pivotal step towards understanding Coartem^®^ resistance in locations where this ACT is a first line strategy, namely in a significant number of African countries, where *pfmdr1* CNV are presently rare, but nevertheless existent [@pone.0020212-Uhlemann1]--[@pone.0020212-Witkowski1].

The precise mechanistic contribution of each one of these mutations remains an open question. From our results and others, a simple model compiling the available data can be proposed ([figure 7](#pone-0020212-g007){ref-type="fig"}), partly extending from previous suggestions [@pone.0020212-Dahlstrom1], [@pone.0020212-Raj1], [@pone.0020212-Sisowath3]. The central assumption is that ART, LUM and MQ drugs have their main pharmacological targets located in the cytoplasmic compartment [@pone.0020212-Sisowath3] while PfMRP1, located in the plasma membrane, pumps them out of the cell, thereby reducing the intra-cytoplasmatic concentrations of the drugs. Pgh-1, inserted in the food vacuole membrane, would contribute to further drug expulsion from the cytoplasm by transporting these drugs towards the lumen of this organelle.

![Proposed model for mode of action of the polymorphisms found.\
The central assumption is that ART, LUM and MQ drugs have their main pharmacological targets located in the cytoplasmic compartment while PfMRP1, operates by reducing the intra-cytoplasmatic concentrations by effluxing them out of the cell. Pgh-1, on its turn will contribute to further drug expulsion from the cytoplasm by transporting these drugs towards the lumen of the food vacuole.](pone.0020212.g007){#pone-0020212-g007}

From our research, we are aware that the *pfmrp1* F1390I SNP is present in the African continent [@pone.0020212-Dahlstrom1]. This is at least the case on the West coast where, incidentally, MQ has been traditionally considered to have lower efficacy compared with the Eastern regions of the continent. No information exists out of SE Asia concerning the *pfmdr1* F1226Y SNP, highlighting the need for more comprehensive studies on this SNP, particularly in Africa, where Coartem^®^ is the most common first line malaria treatment.

In conclusion, we propose novel potential markers of *in vitro* multidrug resistance against ACT drugs, particularly involving the pivotal artesunate-MQ and artemether-LUM combinations. These results further reinforce the complexity of emerging resistance to ACTs, consisting of several different molecular contributions, and hence multiple genetic markers.

Materials and Methods {#s4}
=====================

Ethics statement {#s4a}
----------------

Collection protocols were approved by the Ethical Committee of the Faculty of Tropical Medicine, Mahidol University, Bangkok and Oxford Tropical Research Ethics Committee (OXTREC) at University of Oxford, UK.

The attending physician assured provision of written informed consent in the local language. After having obtained the patients or parents informed consent, venous blood was collected.

Parasites {#s4b}
---------

Isolates of *P. falciparum* were collected from malaria patients before treatment between the year 2002 and 2008 in Mae Sot, Thailand. Forty six isolates were chosen to be enrolled in this study. Parasites were cryo-preserved in liquid nitrogen until further use.

Culture adaptation of the isolates was performed in 5% human O^+^ RBCs in RPMI 1640 culture medium supplemented with 10% L-glutamine, 0.05% gentamicine (Gibco^®^/Invitrogen™, Carlsbad, CA, USA) and 10% human AB^+^ serum. The cultures were incubated at 37°C with addition of a gas mixture (5% O2, 5% CO2 in N2) and shook at 50 rpm.

*In vitro* drug susceptibility assays {#s4c}
-------------------------------------

Chemosensitivity testing *in vitro* was performed with 4 antimalarial drugs. Artemisinin-282.33 MW, dihydroartemisinin-284.35 MW and mefloquine hydrochloride-414.77 MW, were purchased from Sigma-Aldrich (St louis, MO, USA) and lumefantrine-530 MW (LUM) from Novartis (Basel, Switzerland). The drugs were reconstituted in different solvents depending on their solubility. The IC\'s values were assessed using a Histidine-Rich Protein 2 based Double-Site Sandwich Enzyme-Linked Immunosorbent Assay [@pone.0020212-Noedl2]. Briefly, the parasite isolates were cultured (synchronized at ring stage containing 0,05% parasitaemia and 1,5% hematocrite) in the presence of serial dilutions of antimalarial drugs (ART, DHA, LUM and MQ). After 72 hours of culturing at 37°C in candle jars, cells were then lysed by freeze-thawing for ELISA analysis. Four independent assays were performed for each field isolate and 3D7 reference strain IC~50~ measured once a month for drug quality control. 3D7 strain was obtained from Prof. D. Walliker (Department of Animal and population genetics, University of Edinburgh, UK).

Nucleic acids extraction {#s4d}
------------------------

Blood samples from each culture-adapted isolate were centrifuged and 50 µL packed parasitized RBC frozen for DNA extraction. For RNA extraction 150 µL of PBS plus 300 µL of Lysis buffer (Applied Biosystems™, Fresno, CA, USA) were added to 50 µL packed parasitized RBC. The mix was kept at −20°C until RNA extraction. DNA and RNA extraction was carried out using an ABIPRISM^®^6100 Nucleic Acid PrepStation^®^ (Applied Biosystems™, Fresno, CA, USA) according to the recommendations of the manufacturer. cDNA synthesis was carried out using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Fresno, CA, USA).

Drug transporter genes open reading frame sequencing {#s4e}
----------------------------------------------------

All 46 isolates were fully sequenced for *pfmdr1* and *pfmrp1* genes from gDNA and the *pfcrt* gene was sequenced from cDNA. Amplification and sequencing primers for the *pfmrp1* were as described [@pone.0020212-Dahlstrom1] and for *pfmdr1* and *pfcrt* genes the primers are shown in supplementary supporting information ([Material and Methods S1](#pone.0020212.s001){ref-type="supplementary-material"}). Amplicon fragments were sequenced by Macrogen Inc. (Seoul, Korea).

The Sequencher™ software versions 4.6 (Gene Codes Corporation, Ann Arbor, MI) was used to analyze the sequence output with the 3D7 sequence reference of PFE1150w (*pfmdr1*), PFA0590w (*pfmrp1*) and MAL7P1.27 (*pfcrt*) downloaded from Plasmo DataBase (<http://plasmodb.org/>).

Gene copy number amplification of *pfmdr1* and *pfmrp1* {#s4f}
-------------------------------------------------------

Relative quantification of *pfmdr1* and *pfmrp1* genes in all isolates was performed using housekeeping gene tubulin beta chain putative (PF10_0084). TaqMan^®^ probes and primers for *pfmdr1* were as described [@pone.0020212-Price2]. For *pfmrp1*, new primers (fw 5′-AGT AGA AGG AAG AGA CAT TCG AAC ATA-3′ and rev 5′-CAA AAG AAG ATT GAG CTA AAA TAC CAA-3′) and probe (6-FAM, MGBNFQ 5′-AAT AGA AAA GGA GAA GAT AG-3′) were designed (Applied Biosystems™, Fresno, CA, USA) to be performed as a multiplex using the same housekeeping gene primers and probe employed in *pfmdr1* analysis.

*P.falciparum* DNA from 3D7, K1 and FCB reference strains were used as calibrators and positive controls (known copy number variation for *pfmdr1* gene). Multiplex amplification reactions were done in triplicate in 96 well plates with 20 µl containing TaqMan^®^ Gene Expression Mastermix (Applied Biosystems), 300 nM of each forward and reverse primer, 100 nM of TaqMan^®^ probe from both target and housekeeping gene and 4 µL of gDNA. The thermal cycle profile was 50°C 2 min, 95°C 10 min and forty-five cycles of 95°C 15 s and 60°C 1 min. PCR was performed in ABI PRISM® 7000 Sequence Detection System (Applied Biosystems™, Fresno, CA, USA). The detection threshold was set above the mean baseline value for the first 6--15 cycles.

Genotype re-analysis after culture adaptation {#s4g}
---------------------------------------------

To check the existence of any variance or selection of parasites genotypes in the field isolates after *in vitro* adaptation, the DNA was extracted from the culture plates (row "A"/no drug control) in which the last tests for ICs was performed.

Genotyping was done only in the polymorphisms herein observed to be significantly associated with *in vitro* susceptibility: the *pfmdr1* CNV, *pfmdr1* F1226Y and *pfmrp1* F1390I. The method to recheck *pfmdr1* CNV was the same as described above. For *pfmdr1* F1226Y and *pfmrp1* F1390I pyrosequencing was the preferred method due to time/cost efficiency. The pyrosequencing protocol and primers were designed with Pyrosequencing assay design software, version 1.0 (Biotage AB, Uppsala, Sweden). Amplification conditions, pyrosequencing primers and the nucleotide dispensation orders are described in supplementary supporting information ([Material and Methods S1](#pone.0020212.s001){ref-type="supplementary-material"}).

Computational molecular analysis {#s4h}
--------------------------------

Secondary structure analysis of transmembrane spanning domain 2 (TSD2) of PfMRP1 was performed with SOSUI server [@pone.0020212-Hirokawa1]. Computational homology modeling was performed at HHpred-Homology detection & structure prediction by HMM-HMM comparison server (<http://toolkit.tuebingen.mpg.de/hhpred>). Alignment for best template was performed using Psi-blast with 8 interactions and with local alignment. The template from the best E-score alignment for the second transmembrane spanning domain 2 based in the Msba ABC transporter crystal 3B60, was then used in Modeller software to generate a model. Models were visualized with Yasara software [@pone.0020212-Krieger1].

Statistical analysis {#s4i}
--------------------

50% and 90% inhibitory concentrations were calculated by nonlinear regression analysis (<http://malaria.farch.net>). Statistical analysis was carried out using SigmaPlot for windows version 11.0. Pearson Correlation was used to assess linear relations. *In vitro* drug susceptibility phenotype and genotype association ([Table 1](#pone-0020212-t001){ref-type="table"} and [Table S2](#pone.0020212.s003){ref-type="supplementary-material"}) was performed with T-test with equal variances assumed (2-tailed). For comparison, Bonferroni-adjusted level of significance would be: P value \<0.0042. Isolates that harbors both alleles (mixed infection) in the determined polymorphic region were excluded from the statistical analysis.

Supporting Information {#s5}
======================

###### 

PCR program, mastermix and primer sequences for *pfmdr1* and *pfcrt* ORF sequencing and *pfmdr1* F1226Y and *pfmrp1* F1390I genotyping by pyrosequencing.

(DOC)

###### 

Click here for additional data file.

###### 

**Comprehensive data of each isolate genotype and** ***in vitro*** **drug susceptibility values.**

(XLS)

###### 

Click here for additional data file.

###### 

**Relationship between average in vitro drugs tested IC\'s and relevant polymorphisms.**

(XLS)

###### 

Click here for additional data file.
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